RBC Capital analyst Leonid Timashev downgraded Exelixis (EXEL) to Sector Perform from Outperform with a price target of $50, up from $45. The firm believes the shares at current levels are fairly valuing the remaining branded Cabometyx cash flows and probability weighted life-cycle potential ahead of the 2031 patent cliff. RBC wants to see additional life cycle success that can offset the loss of Cabometyx before again recommending shares of Exelixis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis downgraded to Sector Perform from Outperform at RBC Capital
- Truist biotech analyst holds an analyst/industry conference call
- Exelixis price target raised to $53 from $47 at H.C. Wainwright
- Exelixis’s Promising STELLAR-303 Trial Results Lead to Buy Rating and Increased Approval Probability
- NuScale, Hims & Hers, Snowflake, Advance Auto Parts, Exelixis: Trending by Analysts